Adverse facial edema associated with off-label use of recombinant human bone morphogenetic protein-2 in cranial reconstruction for craniosynostosis. Case report.
The authors present a case of scalp and facial edema following craniofacial reconstruction for metopic craniosynostosis in which recombinant human bone morphogenetic protein-2 (rhBMP-2) was used to treat cranial defects related to the frontoorbital reconstruction. The extent of swelling, the onset, and duration were unusual for such cases and suggested a possible role of rhBMP-2 in inducing a local inflammatory response. The edema rapidly resolved after the patient underwent surgery to remove the rhBMP-2 implants.
Shah
M Mohsin
MM
Division of Neurosurgery, University of Missouri-Columbia,Columbia, MO 65203, USA. mmohsinshah@gmail.com
Smyth
Matthew D
MD
Woo
Albert S
AS
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000009:adverse effects*; D001860:Bone Plates; D002675:Child, Preschool; D003393:Cranial Sutures / Q000002:abnormalities / Q000601:surgery; D003398:Craniosynostoses / Q000601:surgery*; D003399:Craniotomy; D004343:Drug Implants; D004487:Edema / Q000139:chemically induced*; D005148:Facial Dermatoses / Q000139:chemically induced*; D005624:Frontal Bone / Q000002:abnormalities / Q000601:surgery; D006801:Humans; D008297:Male; D009915:Orbit / Q000601:surgery; D011994:Recombinant Proteins; D019651:Plastic Surgery Procedures / Q000009:adverse effects*; D012536:Scalp Dermatoses / Q000139:chemically induced; D016212:Transforming Growth Factor beta / Q000009:adverse effects*
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004343:Drug Implants; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta